CBLL (45) CNMD (65) CV (45) TMDX (62) ⌘ Pro Terminal →

InMode Ltd. (INMD) — RQD Stock Rating Cockpit

$13.22 -2.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.14

InMode Ltd. (INMD) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $776.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, InMode Ltd. (NASDAQ: INMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $13.22 (-2.15% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INMD compare to CBLL and CNMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (65/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INMD?

▼

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.14 (-0.58%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMD)Realized 20D OHLCV Swing Band: ±3.2%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY INMD SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 22.7% FCF Margin ($84.3M FCF) & 78.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$14.30-1.6% Next Q

Q2 (-2Q)

Grade C+$14.07-2.5% Next Q

Q3 (-1Q)

Grade C$13.72-3.6% Next Q

Current

Grade D+$13.22+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.34) or 200D SMA ($14.33) invalidates the momentum regime and cuts Target Base ($13.22) toward Bear Floor ($10.31).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

36.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

9.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE13% OF RANGE

L: $13$13.22H: $17

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (79% profit margin and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on INMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (75)

17.7% ROIC with 78.5% gross margin and 10.85% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 9.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

19/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like INMD

✓Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMD)

✓Walkthrough of INMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.62%▼ SUPPORT BREAKDOWN

2026-11-02O $13.37H $13.51L $13.22C $13.22VOL 370.6K

RES: $14.57SUP: $14.01SMA50: $14.34SMA200: $14.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMD Butterfly Map → + Track INMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.3%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMD)

Health Care Rank #200 of 1016 ⚔️ CBLL vs INMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMD vs. CBLL, CNMD, CV, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #200 by composite RQD confidence (58/100, grade D+) and #390 by equity capitalization ($776.6M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with INMD at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMD ACTIVE InMode Ltd.	D+	58/100	—	78.5%	17.7%	-2.15%	$776.6M	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	-4.46%	$1.07B	/cbll-vs-inmd →
CNMD CONMED Corporation	C	65/100	28.9x	54.6%	7.8%	-3.13%	$1.36B	/cnmd-vs-inmd →
CV CapsoVision Inc.	D	45/100	—	52.9%	-35.0%	-1.58%	$369.2M	/cv-vs-inmd →
TMDX TransMedics Group Inc.	C	62/100	12.2x	59.9%	18.1%	-1.68%	$2.33B	/tmdx-vs-inmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001742692

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$370.5M	$0	$85.3M	$84.3M	$766.4M	—
FY2024 (FY)	2024-12-31	$394.8M	$0	$132.7M	$132.0M	$785.7M	—
FY2023 (FY)	2023-12-31	$492.0M	$197.9M	$176.8M	$176.8M	—	—

3. INMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INMD compare to CBLL and CNMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INMD?

Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.22 (-2.15% on volume of 439,914 shares), positioning the stock -7.81% below its 50-day simple moving average ($14.34) and -7.75% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 12.7% percentile with a 14-day RSI of 36.3 (NEUTRAL RANGE) and an implied next-earnings move of ±3.2% ($12.80 to $13.64).

INMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INMD stock right now?

InMode Ltd. (INMD) currently earns a Roarable Rating of D+ (Sell — SELL) with 58/100 RQD Confidence. Stretched risk/reward at current multiples (18% return on capital) under elevated 10-year interest-rate pressure.

What is INMD's 12-month price target and RQD AI Jury consensus?

INMD's 12-month base price target is $13.22 (range $10.31 to $17.5), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INMD RQD Cockpit INMD 12M Forecast INMD Earnings & Move INMD Dividends & DRIP INMD Insiders & 13F INMD Whale Options INMD Profit Sankey INMD News & Why

ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INMD — InMode Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:33:00Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, InMode Ltd. scores 58 out of 100, grading D+ with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 17.7% and an FCF yield of 10.85%. These are the strongest cash-generation signals in the rating and indicate the business has historically converted capital into returns.
Whale 13F Flow: 4 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning and is the weakest pillar, suggesting limited evidence of large-holder accumulation in the source data.
Insider Conviction: 15 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow, scoring mid-range.
Macro Regime Fit: 8 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity, scoring low, which indicates limited alignment with the current macro regime as assessed by the rating.
Forensic Balance Sheet: 16 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 9.2, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. The Z-Score is high, while the Piotroski score is modest.

For a prospective investor evaluating the stock today, the rating implies that the cash-generation and balance-sheet pillars provide support, while weak institutional flow and low macro-regime fit weigh on the overall grade. Investor implications: upside drivers would need to come from improved institutional participation and a stronger macro fit; valuation tradeoffs center on a cash-yield profile that is attractive on the rating's FCF metric but paired with reported net margin of 0%, which limits the earnings-based valuation case. Per the RQD rating's verdict, the rating advises trimming rather than adding exposure.

Business

InMode Ltd. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry, per the company profile. Per the market data, the company reports a gross margin of 78.5% and an operating margin of 23%. The source data does not provide a detailed description of its products, customers, or revenue model beyond sector and industry classification.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$370.5M	$85.4M	$0.0M	N/A	$84.3M	$302.5M	N/A
FY 2024	$394.8M	$112.5M	$0.0M	N/A	$132.0M	$155.3M	N/A
FY 2023	$492.0M	$195.7M	$197.9M	N/A	$176.8M	N/A	N/A

Per the SEC financials, revenue declined from $492.0M in FY 2023 to $394.8M in FY 2024 and $370.5M in FY 2025, while operating income fell from $195.7M to $85.4M over the same span. Per the market data, net margin is 0% and ROIC is 17.7%. Per the RQD rating, the Altman Z-Score is 9.2 and the Piotroski F-Score is 4/9. Per the RQD rating, Debt/Equity is 0.5; the source data does not report total debt values for the financial periods.

Recent Catalysts & News Wire Analysis

Per the news feed, the most prominent catalyst is an announcement that Steel Partners Holdings L.P. issued an open letter and set an October 30, 2026 expiration for its $16.75 per share all-cash offer, rated as a green catalyst. Per the news feed, other items include a consensus target price of $16.00 per a MarketBeat report, a report that InMode's acquisition committee remains in place after a CEO group's proposal expired, and a scheduled Q3 2026 results release on November 11, 2026, with expected Q3 revenue of $91.8 million to $92.0 million and reiterated FY 2026 revenue guidance of $365M–$375M. Per the news feed, a further item is a Stock Traders Daily piece on volatility zones. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream or downstream dependency mapping. Sector and industry classification (Health Care; Electromedical & Electrotherapeutic Apparatus) is the only sector-level information provided. A prospective investor should watch the outcome of the Steel Partners offer and the Q3 2026 results on November 11, 2026, as these items are the only dated events in the source data that could reprice the equity.

Analyst View & Smart Money Ownership

Per the analyst data, no analyst data is available in the source data. The news feed references a consensus target price of $16.00 per a MarketBeat report, but no rating breakdown is provided. Per the holders data, no holder data is available in the source data, so no SEC Form 4, 13F, or Congressional trade detail can be reported.

Open Questions

What are the terms and conditions of the Steel Partners Holdings offer, and how would they interact with the current $13.51 price?
What are the total debt figures and EPS values for the reported periods, which the source data lists as N/A or unavailable?
What is the company's product and customer mix that drives the revenue decline from FY 2023 to FY 2025?
What do the Q3 2026 results, due November 11, 2026, show against the reiterated $365M–$375M FY 2026 revenue guidance?
Who are the institutional and insider holders, since the holders data is not provided?

INMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InMode Ltd. (INMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INMD Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 5h ago

Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer

Yahoo Finance report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 8h ago

InMode Ltd. (NASDAQ:INMD) Stock Has Consensus Target Price of $16.00 According to Analysts

MarketBeat report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 11h ago

After a CEO group's proposal expired, InMode (INMD) keeps its acquisition committee in place.

Stock Titan report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 14h ago

InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

Yahoo Finance report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 17h ago

InMode reiterates USD 365 million outlook: USD 15 target for InMode stock

ad-hoc-news.de report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 20h ago

(INMD) Volatility Zones as Tactical Triggers

Stock Traders Daily report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 23h ago

InMode Ltd. (INMD) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

InMode Q3 2026 Earnings Date and Estimates

MarketBeat report covering InMode Ltd. (INMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INMD Bull vs. Bear Conversation Board — What's Your Call at $13.22?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INMD 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $14.59 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INMD (D+ • RQD 58/100) a Buy at $13.51?

Welcome to the INMD (InMode Ltd.) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to capital efficiency (17.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $11.08 (-18.0%)

Spot @ $13.51

Pump the brakes on INMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INMD, but look at what you are paying: current EV/EBITDA multiples with 78.5% gross margins. Unless InMode Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $17.02 (+26.0%)

Spot @ $13.51

INMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INMD, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $13.51 (52-wk range $12.72 - $16.67), any beat on forward guidance forces shorts and underweight funds to chase.